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Historically,  the  predominant  function  of vitamin  D is well  recognized  in  calcium  and  phos-
phate  homeostasis.  Recently,  plenty  of observational  and  epidemiological  studies  have
suggested  the pro-active  role of  vitamin  D  in  colorectal,  prostate,  breast,  ovarian,  and  skin
cancers. The  protective  role  of  vitamin  D  against  cancer  has  been  attributed  to  its  inﬂuence
on  cell  proliferation,  differentiation,  apoptosis,  DNA  repair  mechanisms,  and  inﬂammation
and  immune  function.  Latest  research  has  identiﬁed  that vitamin  D exerts  antiprolifera-
tive  and  prodifferentiating  effects  in  many  malignant  cells,  and inhibits  the  proliferation  of
malignant  cells  in  animal  models  raising  the  possibility  of its therapeutic  application  as  anitamin D
olorectal carcinoma
5(OH)D
poptosis
alcitriol
anticancer  agent.  The  developed  genomic  models  of  vitamin  D receptors  clearly  illustrate
the  anti-cancer  effects  of  Vitamin  D but till  date,  the  simultaneous  hypercalcemic  effect  of
vitamin  D could  not  be  removed  from  these  analogs.  This  review  presents  various  dimen-
sions  of  anti-cancer  actions  of vitamin  D by  elaborating  its lead role  in  preventing  colorectal
carcinoma,  and  sets  future  goals  for establishing  its therapeutic  actions.© 2013  Saudi  Society  of  Microscopes.  Published  by  Elsevier  Ltd.  All  rights  reserved.
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1. Introduction
The relation between vitamin D status and colorec-
tal cancer (CRC) risk has been coined since 1980 [1]
and researchers have investigated this hypothesis by
various means including direct measures of circulat-
ing 25-hydroxyvitamin D [25(OH)D] levels, surrogates or
determinants of 25(OH)D, covering region of residence,
intake, and sun exposure estimates, or a combination [2–4].
Most  epidemiological studies have reported that higher
serum 25(OH)D levels are associated with lower incidence
rates of colon, breast, and ovarian cancers [5–9] and higher
25(OH)D and 1,25-dihydroxyvitamin D [1,25(OH)2D] with
lower  incidence rates of aggressive prostate cancer [10].
CRC  is the fourth most common human malignant neo-
plasia  worldwide, after lung, breast and prostate cancers,
estimating 1,000,000 new cases (9.4% of total cancer
cases) and 500,000 deaths annually [11]. The general inci-
dence  rates are higher in economically developed countries
of  North America, Australia, Eastern Asia, and Western
Europe, whereas Africa, Latin America and Asia have a
lower  incidence. The incidence of CRC in Kingdom of Saudi
Arabia  is escalating with signiﬁcant rightward shift demon-
strating  a higher prevalence of advanced lesions in young
patients [12]. This profound change in the trends and bio-
logical  behavior of CRC may  be associated with dietary and
environmental factors including suboptimal exposure to
sunlight  and low dietary intake of vitamin D. The current
review extensively explores the carcinogenic effects of low
serum  levels of vitamin D in the development of CRC and
illustrates its preventive role against CRC.
1.1. Physiological role and metabolism of vitamin D
The  prohormone (cholecalciferol), derived from skin
or  diet, is hydroxylated to 25-hydroxycholecalciferol
[25(OH)D3] by the hepatic 25-hydroxylase. Although
25(OH)D is the most abundant form of vitamin D in the
blood,  it has limited capability to bind to the vitamin D
receptor (VDR) for its ﬁnal action. Further hydroxylation by
1-hydroxylase (CYP27B1) to the main biologically active
hormone, 1,25-dihydroxycholecalciferol (1,25-(OH)2D3
or calcitriol) takes place in the proximal renal tubule [13].
Sufﬁcient renal production of 1,25-(OH)2D3 leads to acti-
vation  of the catabolic pathway by 24-hydroxylation of
1,25(OH)-D3, or of 25(OH)-D3. A major part of 25(OH)-D3
and of 1,25-(OH)2-D3 is bound in plasma to a vitamin D
binding protein (DBP, 85–87%), which modulates bioavail-
ability and inﬂuences responsiveness in some end-organs
or  to albumin (12%).
1.2.  Dietary and supplemental vitamin D and colorectal
carcinoma
The secosteroid hormone vitamin D can be obtained
from either nutritional origin or it can be produced
in the skin by a photochemical conversion of 7-
dehydrocholesterol to previtamin D and subsequently
to vitamin D under the inﬂuence of ultraviolet rays in
sunlight [14]. The evidence to date suggests that daily
intake of 1000–2000 IU/day of vitamin D3 could reduced Ultrastructure 2 (2014) 1–6
the  incidence of CRC with minimal risk [15]. The Women’s
Health Initiative reported that a low dose of vitamin D
did  not protect against colorectal cancer within 7 years of
follow-up;  however, a meta-analysis indicates that a higher
dose  may  reduce its incidence [16].
Majority of the cohort studies explored the association
between CRC risk and dietary or supplementary vitamin D
in  men  [17,18] and women [19] or both sexes [16,20], and
several  case–control studies [21–23] found inverse associ-
ations for colon or rectal cancer, or both [24]. Most of the
biological actions of 1,25(OH)2D3 are transduced by VDR,
which  is a member of the nuclear receptor superfamily
of ligand-dependent transcription factors. VDR speciﬁcally
acts  as a heterodimer with retinoid X receptor by bind-
ing  to speciﬁc genomic DNA sequences known as vitamin
D  response elements, located at the regulatory regions of
target  genes. The interaction of 1,25(OH)2D3 with VDR
induces allosteric changes in its ligand-binding domain
and  enables the recruitment of co-activators which induce
chromatin decondensation, RNA polymerase II recruitment
and  transcriptional activation [25]. Although the main
physiological role of 1,25(OH)2D3 is the control of cal-
cium homeostasis, however, compelling epidemiological,
animal and molecular reports suggest unique regulatory
actions of vitamin D in preventing a wide range of cancers
including CRC.
1.3.  Sunlight, vitamin D and colorectal carcinoma
The geographic distribution of CRC deaths has reported
that CRC mortality rates were higher in the northern
regions of United States and Europe. Additional research
pointed out a high correlation between latitude and risk
of  CRC in the United States and Europe. People living at
higher  latitudes, presumably by synthesizing less vitamin
D,  have a higher risk of dying from many common cancers
including CRC. These observations are in line with those
which  revealed that CRC mortality in the United States was
higher  in places where people were exposed to the lowest
mean  solar radiation, suggesting that vitamin D may  play a
protective  role in CRC [1]. On the same note, published lit-
erature  is replete with epidemiologic studies showing that
high  vitamin D intake and high plasma levels of 25(OH)D3
were associated with a substantial reduction of CRC inci-
dence  [26].
1.4.  Genetic basis of colorectal carcinoma
CRC originates from the neoplastic transformation of
epithelial cells of the colon and rectum, leading to the accu-
mulation of genetic and epigenetic aberrations [27]. CRC is
thought  to be a result of a series of genetic mutations, which
parallel  histopathologic and molecular changes, from nor-
mal  colonic epithelium to invasive carcinoma. At least four
sequential genetic changes, affecting one oncogen (KRAS)
and  three tumor suppressor genes (APC, SMAD4 and TP53),
are  required for the development of CRC. Mutation of apc
is  often the initiating genetic lesion in CRCs that develop
along the chromosomal instability pathway. Depending on
the  cellular context, loss of apc activates the signaling path-
way  causing immediate widespread apoptosis of colorectal
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pithelial cells and defects in differentiation and cell migra-
ion.  Only cells that are inherently resistant to apoptosis
urvive this initial wave of apoptosis. These surviving cells
onstitute  the epithelial population that develops into ade-
omas  [28].
.  Literature review
.1.  Colorectal carcinoma and vitamin D
A signiﬁcant number of observational and epidemiolog-
cal studies have illustrated an inverse association between
ntake  of vitamin D and the risk of CRC [4,15,29]. A quan-
itative meta-analysis by Gorham et al. suggested that a
erum  25(OH)D level of >33 ng/mL could be associated with
0%  lower incidence of CRC, compared to serum 25(OH)D
12  ng/mL [15]. The results of ﬁve serum studies were com-
ined  using standard methods for pooled analysis. The
ooled  results were divided into quintiles with median
5(OH)D values of 6, 16, 22, 27, and 37 ng/mL. The pooled
dds  ratio for the highest quintile versus the lowest was
.49  (p < 0.0001, 95% conﬁdence interval, 0.35–0.68). Daily
ntake  of 1000 IU would raise the median population serum
evels  to 33 ng/mL, this is less than optimal because 50% of
he  population would still be less than this median level. On
he  contrary, an intake of 2000 IU/day, would raise the pop-
lation  median level to 46 ng/mL. This dose of Vitamin D is
uch  lower than the suggested toxic dose of 5000 IU/day,
hich  would lead to hypervitaminosis with consequent
oxicity.
An experimental study by Spina et al. [30] using human
olon cancer cells (MC-26) grafted into Balb/C mice found
hat  dietary vitamin D repletion reduced the volume
f colon cancer-derived tumors by 40%. Another report
emonstrated that dietary vitamin D repletion reduced the
olume  of colon cancer xenografts in Balb/C mice by 60%
31].  Similarly in a subset analysis of patients from the
HI  trial [16], the odd ratio for CRC was 2.5 for women
ith 25OHD levels below 12 ng/mL versus women with
evels  above 24 ng/mL. Unfortunately, several other studies
ailed  to conﬁrm such a relation [32,33]. Such observa-
ions strongly suggest the role of interventional studies to
etermine  whether vitamin D supplementation can pro-
ect  against CRC and if so, which dosage or 25(OH)D serum
evel  would sufﬁce to provide protection.
.2. Colorectal adenomas and vitamin D
Up to 90% of CRCs are estimated to originate from colo-
ectal adenomas [34]. In a meta-analysis, by Wei  et al.
35],  of studies published before December 2007, a statisti-
ally  signiﬁcant 30% lower risk of colorectal adenomas was
eported  comparing highest versus lowest level of circulat-
ng  25(OH)D. In their case–control study, Takahashi et al.
36]  found that higher circulating 25(OH)D concentrations
ere associated with decreased prevalence of colorectal
denomas only during winter season of blood collection in
apanese  men. Circulating 25(OH)D levels during summer
eason were positively associated with prevalence of colo-
ectal  adenomas. Further research is required to explaind Ultrastructure 2 (2014) 1–6 3
the  role of season-speciﬁc 25(OH)D levels in development
of colorectal neoplasms.
A  recent meta-analysis by Yin et al. [37] demonstrated
incident colorectal adenomas according to serum 25(OH)D
in  8 studies, and colorectal adenomas recurrence in 2 stud-
ies,  respectively. Results summary reported odd ratios (95%
conﬁdence intervals) regarding incident and recurrent
colorectal adenomas, and both outcomes combined were
0.82  (0.69–0.97), 0.87 (0.56–1.35), and 0.84 (0.72–0.97),
respectively, for an increase of 25(OH)D by 20 ng/mL.
Published literature suggests that the risk of colorectal ade-
noma  is lowest when both calcium intake and vitamin D
status  are higher [32,38]. Similarly, among those with high
circulating 25(OH)D levels, those who  also had low cal-
cium  intakes were at lower risk for colorectal adenoma
than those who also had high calcium intakes [39].
2.3.  Anti-cancer roles of vitamin D in colorectal
carcinoma
2.3.1. Preventive role of vitamin D in colorectal cancer
a.  Proliferation inhibition action by 1,25(OH)2D3 and its
analogs in human colon cancer cells contributes to the
anti-cancer mechanisms of vitamin D [40]. The anti-
proliferative effect of vitamin D is attained by inducing
G1 cell-cycle arrest, which is probably mediated by up-
regulation of cell-cycle inhibitors, such as p21WAF1/CIP
and p27KIP. Vitamin D modulates the activation of
these cell cycle related genes by various intricate chan-
nels. p21 contains a vitamin D response elements in its
promoter region, and therefore is susceptible of direct
transcriptional control by vitamin D.
b.  Vitamin D interferes with the synthesis of growth
factors and cytokines by modulating their signaling
pathways.  Normal colonic epithelial proliferation is
inhibited by TGF- signaling and this disruption of TGF-
 signaling is involved in CRC malignant progression. In
some models, vitamin D can restore sensitivity to TGF-
by inducing the expression of the TGF-1 receptor [41].
c.  Vitamin D modulates the differentiation of colon can-
cer cells. In Caco-2 and HT-29 cells, treatment with
1,25(OH)2D3 enhances morphological differentiation
parameters,  such as the number of desmosomes,
inter-mediate ﬁlaments and microvilli length and den-
sity. Moreover, 1,25(OH)2D3 markedly enhances the
expression and activity of alkaline phosphatase, a
marker of colonic differentiation.
d. Induction of apoptosis is directly linked with the anti-
cancer action of vitamin D. This mechanism is regulated
by the up-regulation of the pro-apoptotic protein bak
and the down-regulation of the anti-apoptotic protein
bcl-2 [27]. Vitamin D activates the intrinsic pathway
of apoptosis causing the disruption of mitochondrial
function,  cytochrome release and production of reactive
oxygen species [42,43]. Vitamin D also directly activates
caspases to induce apoptosis [44]. A subjective algo-
rithm of apoptosis is displayed in Fig. 1 [45].e.  In addition to vitamin D, VDR modulates the actions of a
secondary bile acid, lithocholic acid. Fat-rich diets con-
tain high levels of lithocholic acid, which inﬂicts DNA
damage in normal colon cells and, therefore, increases
4 S.Y. Guraya / Journal of Microscopy and Ultrastructure 2 (2014) 1–6
Fig. 1. Intrinsic and extrinsic cascades of vitamin D-induced apoptosis.
1,25-Dihydroxy vitamin D3 [1,25-(OH)2D3] up-regulates the pro-
apoptotic protein bak and down-regulates the anti-apoptotic protein
bacl-2. Pro-apoptotic and anti-apoptotic bcl-2 modulate the release of
cytochrome c and other pro-apoptotic factors. Cytochrome c integrates
with APAF-1 and pro-caspase 9 to form the apoptosome, which stimamu-
lates caspase 3 activation, inducing the cleavage of different substrates
in apoptotic cells. Another bcl-2-family member, BID, when cleaved
by caspase 8 (tBID), translocates to the mitochondria membrane and
triggers the mitochondria-dependent or intrinsic death pathway. BID con-
nects  the extrinsic (death-receptor mediated cell death pathway) and
the  intrinsic death pathways. In cancer cells, 1,25-(OH)2D3 induces
the down-regulation of inhibitor of apoptosis proteins (IAP). APAF-1,
apoptotic protease activating factor-1; BAK, Bcl-2-antagonist killer; BAX,
Table 1
Chemopreventive effects of vitamin D in colorectal carcinomas.
No. Effects
1. Anti-proliferative
2.  Induction of differentiation
3. Apoptosis
4. Inhibition of growth factor and cytokines synthesis
5. Induction of hypercalcemia
6. Anti-inﬂammatory
7.  Inhibition of tumor cell-induced angiogenesisBcl-2-associated X protein; tBID, truncated BH3-interacting domain death
agonist; BCL-2, B-cell CLL/lymphoma-2 protein; BCL-XL, BCL2-related
protein, long isoform; FADD, FAS-associated death domain.
the risk of CRC. Activation of VDR by either lithocholic
acid  or vitamin D up-regulates CYP3A, SULT2A1, and
MRP3 gene transcription; these proteins are involved
in the detoxiﬁcation of lithocholic acid in the liver and
intestine [11].
f. Calcium intake is associated with lower risk of CRC
[46,47]. However, because 90–95% of circulating vita-
min D and its metabolites result from exposure to
solar ultraviolet rays [48,49], there is little correlation
between intake of calcium and serum 25(OH)D levels.
Feskanich et al. [50] controlled for calcium intake and
could not identify the inﬂuence of calcium on the results
for 25(OH)D. In another study, calcium intake was iden-
tical (1300 mg/day) in cases and controls, and therefore
could not account for the inverse association of serum
25(OH)D with CRC risk [50].8.  Induction of mitogen-activated protein kinase
cascade
9.  Inhibition of stress-activated kinase signaling
g. Since inﬂammation plays important role in can-
cer development [51], vitamin D exerts a strong
anti-inﬂammatory role in delaying or preventing can-
cer development and/or progression [52]. Vitamin D
exhibits antiinﬂammatory actions that may  contribute
to its beneﬁcial effects in several cancers. Krishnan et al.
[53] used cDNA microarrays to discover the molecular
pathways that mediate the anticancer effects of cal-
citriol in PCa cells. The results showed that calcitriol
regulation of gene expression leads to the inhibition
of the synthesis and biologic actions of prostaglandins
(PGs),  stress-activated kinase signaling, and production
of proinﬂammatory cytokines.
h. Calcitriol is a potent inhibitor of tumor cell-induced
angiogenesis  in experimental models [54]. Calcitriol
inhibits vascular endothelial growth factor (VEGF)-
induced endothelial cell tube formation in vitro and
decreases tumor vascularization in vivo in mice bear-
ing xenografts of BCa cells over-expressing VEGF [55].
Calcitriol and its analogs also directly inhibit the prolif-
eration of endothelial cells leading to the inhibition of
angiogenesis [56].
i. Calcitriol induces mitogen-activated protein kinase
activitation and inhibition of stress-activated kinase
signaling and thus exerts a powerful anti-cancer effect
on all cell lines [57].
A summary of the chemopreventive effects of vitamin
D  in CRC is presented in Table 1.
2.3.2. Therapeutic role of vitamin D in colorectal cancer
In  the presence of sufﬁcient preclinical evidence that
high-dose of vitamin D exerts objective anticancer effects,
a  wealth of preclinical trials has been carried out to test this
hypothesis in humans [58,59]. Various vitamin D analogs
have  been tried (e.g. seocalcitol, inecalcitol, paricalcitol),
but calcitriol is by far the most frequently used, both as a
single  agent and as part of a combination regimen. Overall,
single  agent vitamin D has not been consistently associated
with objective tumor response in phase I–II trials enrolling
cancer patients. The main hurdle in developing vitamin D
analogs  for the treatment of cancer is the difﬁculty in sep-
arating  the calcemic activity of vitamin D analogs from its
antiproliferative activity [60]. Despite the positive results
obtained with 1,25(OH)2D3 analogs when analyzed with
in  vitro and in vivo rodents models of colon carcinogene-
sis, they are shown to be of sub-optimal efﬁcacy in clinical
assays.
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More than a thousand analogs of vitamin D have been
eveloped to date and certain analogs have been effec-
ively used as antiproliferative agents in the treatment of
soriasis.  However, to date, there are few clinical trials tes-
ifying  the therapeutic efﬁcacy of vitamin D analogs in CRC
reatment. One promising study has reported that vitamin
 analog seocalcitol was  effective in treating inoperable
epatocellular carcinoma [61]. Serious efforts are being
ade  to design new VDR ligands exhibiting improved ther-
peutic  impact, and to establish new strategies for CRC
hemoprevention based on these ligands. The combina-
ion of vitamin D analogs with other anti-tumor agents
i.e.  chemotherapeutic drugs, epigenetic drugs, etc.) may
esult  in enhanced anti-cancer efﬁciency. A big effort is
eing  made to develop novel synthetic VDR ligands that
an  dissociate the beneﬁcial activities from the undesired
ypercalcemic effects.
.  Conclusion
Despite the wealth of clinical trials conducted so far,
ttempting to establish the therapeutic efﬁcacy of vita-
in  D, there are no reported randomized controlled trials,
hich  can conﬁrm the therapeutic efﬁcacy of vitamin D for
RC.  However, the preventive role of vitamin D in CRC is
ell  recognized and globally accepted. There is a need to
urther  explore the therapeutic potential of vitamin D and
ts  non-calcemic analogs in CRC.
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